Ovarian Malignancy Panel (Screening) – Serum/Plasma

This test measures the level of a specific protein in your blood that is commonly associated with ovarian cancer. Doctors use this measurement, together with imaging and other findings, to help evaluate ovarian health, assess certain symptoms, and guide the next steps in your care.

The ovarian malignancy screening panel typically includes markers that reflect ovarian cancer activity, such as proteins or substances that may be elevated in cancerous tissue. These may include substances like CA-125 (a common ovarian cancer biomarker) and others identified through advanced testing methods.

You may need this test if you have symptoms that could point to an ovarian condition, such as persistent pelvic pain, bloating, or abdominal swelling, or if you have an ovarian mass that your doctor wants to evaluate more closely. It can also be used to monitor how treatment is working or to check for signs that the condition has returned during follow-up visits.

You may have this test if you have symptoms like persistent abdominal or pelvic pain, bloating, or unexplained weight changes. It’s also used in follow-up for women at higher risk due to family history, genetic conditions, or previous ovarian cancer diagnosis.

This test requires a blood sample, which is usually drawn from a vein in your arm. Fasting is generally not necessary, but always follow the specific instructions given by your doctor or the laboratory. Let your healthcare provider know about any medicines or supplements you take, and drink plenty of water beforehand to make the blood draw easier.

Blood is drawn from a vein, usually in your arm. The sample is sent to a lab for analysis. The test uses serum or plasma, depending on the specific methods applied.

The specimen used for this test is a small sample of your blood, collected into a special tube in the laboratory. Once received, the sample is analyzed with precise methods to measure the marker level, and the results are reported to your doctor, typically within a few business days.

The test may use immunoassays (like clia or fia) or other sensitive techniques to detect and quantify specific biomarkers. These methods help distinguish between normal and abnormal levels of substances linked to ovarian cancer.